Latest Breaking News On - Arunj sanyal - Page 6 : comparemela.com

Intercept Pharma (ICPT) Reports Efficacy and Safety Data from Phase 3 REGENERATE Study

Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022

Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis. | October 31, 2022

Lipocine : EFFICACY, SAFETY, AND TOLERABILITY OF CONTINUED LPCN 1144 TREATMENT IN NONALCOHOLIC STEATOHEPATITIS (NASH) SUBJECTS WITH FIBROSIS IN AN OPEN LABEL EXTENSION STUDY (OLE) - Form 8-K

EFFICACY, SAFETY, AND TOLERABILITY OF CONTINUED LPCN 1144 TREATMENT IN NONALCOHOLIC STEATOHEPATITIS SUBJECTS WITH FIBROSIS IN AN OPEN LABEL EXTENSION STUDY Benjamin J Bruno1,. | October 27, 2022

Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022

/PRNewswire/ New TARGET-NASH data shows longitudinal trajectories of alanine aminotransferase (ALT) remained comparatively stable among patients with.

HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials

This is a first-of-its-kind international study initiated in 2019 by HistoIndex to examine artificial intelligence (AI)-based approaches that may provide a.